The pharmaceutical industry is characterized by fierce competition and relentless innovation, making any significant developments within multinational pharmaceutical companies a point of interest for stakeholders around the worldThe 2025 JPMorgan Healthcare Conference stands as a beacon for the direction the biopharmaceutical sector will take in the coming years, bringing together heavyweights like Johnson & Johnson, Pfizer, and Merck to outline their strategic roadmaps.

As patent expiration deadlines approach, the specter of the so-called "patent cliff" looms larger, with estimates indicating over $100 billion worth of drugs will lose patent protection before 2030. This impending challenge is forcing pharmaceutical giants to ask themselves a crucial question: how can they sustain growth?

This year, unlike those in the past, the conference showcased a shift towards more pragmatic and diversified strategies

Advertisements

In the face of intricate and turbulent market dynamics, some companies exhibited an unprecedented level of caution and agility, while others displayed unyielding optimism and confidence in their commitment to innovation and ambitious goals.

Growth remains the perennial themeEach company is striving to create strategies that align with a rapidly changing landscape and convince investors of their capability to meet projected goalsA pivotal year, 2025 will act as a litmus test for these corporations, evaluating their adaptability as well as their long-term vision.

Among the major players, Merck, Pfizer, and Bristol-Myers Squibb (BMS) are facing the charge of the "loss of exclusivity" (LOE) wave with varying degrees of optimism and apprehensionEach CEO took to the stage on the first day of the JPM conference, addressing investors’ concerns regarding the impact of patent expirations on their bottom lines and outlining their plans to mitigate these risks.

Pfizer's CEO, Albert Bourla, warned of an "LOE wave" approaching silently, which could jeopardize between $17 billion to $18 billion in sales

Advertisements

To counteract this threat, Pfizer has pursued a series of acquisitions aimed at bolstering its portfolio, including the purchases of Seagen and BiohavenBourla projected that by 2030, these acquisitions could contribute upwards of $20 billion in sales, enough to offset potential losses from any forthcoming patent expirationsAdditionally, Pfizer is banking on the success of its late-stage clinical trials, such as its CDK4 inhibitor abemaciclib, which is positioned to address HR-positive, HER2-negative metastatic breast cancer.

As for BMS, the outlook appears to be considerably more dauntingCEO Chris Boerner revealed that BMS's exposure to LOE risks is set to increase, particularly with Revlimid, which is anticipated to face a host of generic competitors in March 2025, leading into a full generics market by 2026. Revlimid alone generated $4.4 billion in revenue in Q1 of last year but is forecasted to plummet to as low as $2 billion to $2.5 billion by 2025 due to these competitive pressures

Advertisements

Coupled with projected losses from Pomalyst and Sprycel, BMS expects to see a “cumulative effect” this year.

BMS isn’t standing idle, howeverBoerner highlighted that the company is currently progressing on around 40 projects in late-stage developmentAiming for resilience, BMS plans to launch ten new drugs and expand indications for at least 30 treatments over the next five years, including breakthroughs from acquisitions such as the schizophrenia drug KarXT.

Merck, represented by CEO Rob Davis, expressed a different tone regarding future prospectsDespite the threats posed by the imminent LOE cliff, Davis shared that Merck’s late-stage assets are set to nearly double by 2024 compared to 2021, fueled by approximately $40 billion invested in business development transactionsThe company anticipates breakthroughs from 13 product launches across various therapeutic areas, including oncology and immunology, reflecting Davis’s confidence in achieving $25 billion in revenue by 2030 from its oncology portfolio alone.

Meanwhile, companies like Regeneron, Bayer, and Gilead find themselves in need of additional momentum to propel their operations forward

• Companies Step Up Market Value Management Efforts
• Brokerages Boost Dividend Asset Allocation
• Retail in 2025: No Room for Myths
• The Patent Cliff Showdown of MNCs
• Why is Aux Electric Committed to the IPO Journey?

Bayer’s prescription division president, Stefan Oelrich, introduced several new product launches aimed at mitigating the impact of the patent expiration for XareltoBayer eyes the introduction of three major new drugs—including a menopause treatment and a cardiovascular drug—due by 2026 while implementing organizational changes to streamline efficiency and speed up decision-making processes.

On the other hand, Regeneron maintains its focus on in-house development, while Gilead admits to leveraging acquisitionsAs Regeneron unfolds its partial revenue reports for Q4 2024, its Eylea HD drug showed mixed performance, falling short of expectations and prompting calls for stronger competition against rivals like Roche’s Vabysmo.

In contrast, Gilead is taking steps to bolster its pipeline through strategic purchases; CEO Dan O'Day emphasized the company’s financial reserves would enable opportunistic acquisitions

Recently, Gilead secured a deal worth $1.7 billion with Leo Pharma, aiming to strengthen its pipeline with STAT6 inhibitors.

The looming threat of losing market exclusivity for major drugs is compelling manufacturers to harness innovative solutionsGilead looks ahead at a range of new-generation HIV products to mitigate the loss of Biktarvy's exclusivity by 2033, bolstered by confidence in the injections like lenacapavir that promise to be groundbreaking in HIV prevention and treatment.

In stark contrast to the strategies adopted by some peers, AstraZeneca remains exceptionally optimisticThe company reiterated its ambitious forecast of reaching $80 billion in revenue by 2030, bolstered by growth in oncology, cardiovascular, and rare disease sectorsThe surge in sales partly comes from a robust pipeline, with a projected increase of a staggering number of blockbuster drugs in various stages of development aimed at addressing urgent medical needs.

Roche is aggressively pursuing a strategy of innovation and acquisition to navigate its way out of the patent cliff

Its portfolio has been successfully overhauled with new products, while CEO Teresa Graham announced an annual cash reserve of $10 billion earmarked for strategic acquisitions aimed at bolstering key therapeutic areas.

Interestingly, Novartis is taking a different routeThis giant in the pharmaceutical industry has not sequestered itself into the comfort of blockbuster drugsInstead, it embraces a diversified portfolio focusing on gene therapy, cell therapy, and small molecule pharmaceuticals, predicting sustained growth underpinned by innovations in important drug classes.

Ultimately, all pharmaceutical companies are engaged in an endless quest for sustainable and healthy growthThe stark reality is that companies, regardless of size or influence, must remain innovative, either through high-yield research and development or strategic mergers and acquisitionsWhile larger companies may find it easier to acquire, they also face heightened scrutiny and pressure to perform.

This year’s JPM conference has illuminated both the ambitions and the challenges that lie ahead for these pharmaceutical firms